PDCD1 and neoplasm: When the tumor is treated with both OVT and anti-PD-1, Figure 12A shows the tumor size after 300 h as the source of innate immune cells, sZR varies, in the baseline case and when paired with a strong adaptive immune response, represented by an increased aAT.